Clonal hematopoiesis in cardiovascular aging: Insights from the verona heart study.
Aging
Clonal hematopoiesis
Coronary artery disease
Somatic mutations
Journal
GeroScience
ISSN: 2509-2723
Titre abrégé: Geroscience
Pays: Switzerland
ID NLM: 101686284
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
04
06
2024
accepted:
25
09
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
aheadofprint
Résumé
Clonal hematopoiesis of indeterminate potential (CHIP), marked by the accumulation of somatic mutations in hematopoietic stem cells, significantly elevates the risk of all-cause mortality, mainly due to cardiovascular events. Therefore, investigating this pathophysiological phenomenon is crucial for understanding cardiovascular aging and enhancing both health span and lifespan. In the present study, we examined samples of subjects enrolled within the angiographically controlled Verona Heart Study (VHS), which provides a robust model for cardiovascular aging, particularly regarding coronary artery disease (CAD). We analyzed 44 older subjects diagnosed with coronary artery disease (CAD) and 42 healthy, sex- and age-matched controls (CAD-FREE). Employing deep sequencing and an amplicon-based approach, we focused on 11 key genetic regions in ASXL1, DNMT3A, IDH1, IDH2, JAK2, PPM1D, SF3B1, SRSF2, TET2, TP53, and U2AF1 genes to investigate clonal hematopoiesis. Subjects in the CAD group exhibited a significantly higher variant burden than those in the CAD-FREE group, both in terms of the total number of somatic variants and disruptive variants affecting protein function. This increased mutational load was notably influenced by six specific genetic regions: ASXL1, DNMT3A, IDH2, JAK2, TET2, and U2AF1, which displayed elevated variant rates in the CAD subjects. Moreover, ASXL1, DNMT3A, IDH2, JAK2, SF3B1, TET2, and TP53 exhibited substantially higher levels of disruptive variants in the CAD group. In summary, our findings highlight a correlation between clonal hematopoiesis and the accumulation of disruptive variants in specific genomic regions in the VHS cohort, thereby shedding light on their potential role in cardiovascular aging.
Identifiants
pubmed: 39460851
doi: 10.1007/s11357-024-01367-x
pii: 10.1007/s11357-024-01367-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to American Aging Association.
Références
Miles B, Tadi P. Genetics, Somatic mutation [Internet]. [Updated 2023 Apr 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.; Available from: https://www.ncbi.nlm.nih.gov/books/NBK557896/
Garagnani P, Marquis J, Delledonne M, Pirazzini C, Marasco E, Kwiatkowska KM, et al. Whole-genome sequencing analysis of semi-supercentenarians. eLife. 2021;4:10:e57849
Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477–87.
doi: 10.1056/NEJMoa1409405
pubmed: 25426838
pmcid: 4290021
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488–98.
doi: 10.1056/NEJMoa1408617
pubmed: 25426837
pmcid: 4306669
Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130(6):742–52.
doi: 10.1182/blood-2017-02-769869
pubmed: 28483762
pmcid: 5553576
Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377(2):111–21.
doi: 10.1056/NEJMoa1701719
pubmed: 28636844
pmcid: 6717509
Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98–105.
doi: 10.1016/j.yjmcc.2021.07.004
pubmed: 34298011
pmcid: 8629838
Nakao T, Natarajan P. Clonal hematopoiesis, multi-omics and coronary artery disease. Nat Cardiovasc Res. 2022;1(11):965–7.
doi: 10.1038/s44161-022-00154-1
pubmed: 36339018
pmcid: 9628526
Haring B, Wissel S, Manson JE. Somatic mutations and clonal hematopoiesis as drivers of age-related cardiovascular risk. Curr Cardiol Rep. 2022;24(8):1049–58.
doi: 10.1007/s11886-022-01724-2
pubmed: 35657494
pmcid: 9329391
Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20(11):754–77.
doi: 10.1038/s41569-023-00881-3
pubmed: 37193857
Martinelli N, Girelli D, Lunghi B, Pinotti M, Marchetti G, Malerba G, et al. Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile. Blood. 2010;116(25):5688–97.
doi: 10.1182/blood-2010-03-277079
pubmed: 20810930
Martinelli N, Girelli D, Baroni M, Guarini P, Sandri M, Lunghi B, et al. Activated factor VII–antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study. J Thromb Haemost. 2016;14(4):655–66.
doi: 10.1111/jth.13274
pubmed: 27061056
Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011 Jan 1;39(Database):D945–50.
Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017;1:1–16.
doi: 10.1200/PO.17.00011
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.
doi: 10.1158/2159-8290.CD-12-0095
pubmed: 22588877
Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862–8.
doi: 10.1093/nar/gkv1222
pubmed: 26582918
Lever J, Jones MR, Danos AM, Krysiak K, Bonakdar M, Grewal JK, et al. Text-mining clinically relevant cancer biomarkers for curation into the CIViC database. Genome Med. 2019;11(1):78.
doi: 10.1186/s13073-019-0686-y
pubmed: 31796060
pmcid: 6891984
Pagel KA, Kim R, Moad K, Busby B, Zheng L, Tokheim C, et al. Integrated informatics analysis of cancer-related variants. JCO Clin Cancer Inform. 2020;4:310–7.
doi: 10.1200/CCI.19.00132
pubmed: 32228266
Tokheim C, Karchin R. CHASMplus reveals the scope of somatic missense mutations driving human cancers. Cell Syst. 2019;9(1):9-23.e8.
doi: 10.1016/j.cels.2019.05.005
pubmed: 31202631
pmcid: 6857794
Rogers MF, Shihab HA, Gaunt TR, Campbell C. CScape: a tool for predicting oncogenic single-point mutations in the cancer genome. Sci Rep. 2017;7(1):11597.
doi: 10.1038/s41598-017-11746-4
pubmed: 28912487
pmcid: 5599557
National Comprehensive Cancer Network. Myelodysplastic syndromes (Version 3.2024) [Internet]. 2024 [cited 2024 Sep 7]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703–19.
Higgins-Chen AT, Thrush KL, Wang Y, Minteer CJ, Kuo PL, Wang M, et al. A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking. Nat Aging. 2022;2(7):644–61.
doi: 10.1038/s43587-022-00248-2
pubmed: 36277076
pmcid: 9586209
Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020;52(4):378–87.
doi: 10.1038/s41588-020-0595-4
pubmed: 32203468
pmcid: 7216752
Nachun D, Lu AT, Bick AG, Natarajan P, Weinstock J, Szeto MD, et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell. 2021;20(6):e13366.
doi: 10.1111/acel.13366
pubmed: 34050697
pmcid: 8208788
Jiang R, Hauser ER, Kwee LC, Shah SH, Regan JA, Huebner JL, et al. The association of accelerated epigenetic age with all-cause mortality in cardiac catheterization patients as mediated by vascular and cardiometabolic outcomes. Clin Epigenetics. 2022;14(1):165.
doi: 10.1186/s13148-022-01380-x
pubmed: 36461124
pmcid: 9719253
Salameh Y, Bejaoui Y, El Hajj N. DNA methylation biomarkers in aging and age-related diseases. Front Genet. 2020;11:171.
doi: 10.3389/fgene.2020.00171
pubmed: 32211026
pmcid: 7076122
Assmus B, Cremer S, Kirschbaum K, Culmann D, Kiefer K, Dorsheimer L, et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur Heart J. 2021;42(3):257–65.
doi: 10.1093/eurheartj/ehaa845
pubmed: 33241418
Mas-Peiro S, Hoffmann J, Fichtlscherer S, Dorsheimer L, Rieger MA, Dimmeler S, et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur Heart J. 2020;41(8):933–9.
doi: 10.1093/eurheartj/ehz591
pubmed: 31504400
Dregoesc MI, Tercan H, Țigu AB, Bekkering S, Joosten LA, Netea MG, et al. Clonal hematopoiesis is associated with cardiovascular events in patients with stable coronary artery disease. iScience. 2024;27(4):109472.
doi: 10.1016/j.isci.2024.109472
pubmed: 38558938
pmcid: 10981089
Kessler MD, Damask A, O’Keeffe S, Van Meter M, Banerjee N, Semrau S, et al. Exome sequencing of 628,388 individuals identifies common and rare variant associations with clonal hematopoiesis phenotypes. medRxiv. 2022 Jan 1;2021.12.29.21268342.